DD142547A5 - Verfahren zur herstellung von als neuromuskulaere blockierungsmittel verwendbaren verbindungen - Google Patents

Verfahren zur herstellung von als neuromuskulaere blockierungsmittel verwendbaren verbindungen Download PDF

Info

Publication number: DD142547A5
Authority: DD; German Democratic Republic
Prior art keywords: general formula; item; compound; radical; items
Prior art date: 1978-07-21

Application number

DD79210690A

Other languages

German (de)

English (en)

Inventor

John J Savarese

Richard J Kitz

Sara Ginsburg

Original Assignee

Massachusetts Gen Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-07-21

Filing date

1979-01-29

Publication date

1980-07-02

1979-01-29 Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital

1980-07-02 Publication of DD142547A5 publication Critical patent/DD142547A5/de

Links

150000001875 compounds Chemical class 0.000 title claims description 63
239000000842 neuromuscular blocking agent Substances 0.000 title description 13
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 claims description 82
-1 alkyl radical Chemical class 0.000 claims description 30
238000002360 preparation method Methods 0.000 claims description 30
230000008569 process Effects 0.000 claims description 24
150000003839 salts Chemical class 0.000 claims description 20
238000006243 chemical reaction Methods 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 14
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 13
150000002148 esters Chemical class 0.000 claims description 13
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
150000003254 radicals Chemical class 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
150000001450 anions Chemical class 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 10
239000011541 reaction mixture Substances 0.000 claims description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims description 7
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
150000001768 cations Chemical class 0.000 claims description 6
238000010992 reflux Methods 0.000 claims description 5
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
239000000460 chlorine Substances 0.000 claims description 4
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical group OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical group CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
239000010452 phosphate Chemical group 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 2
229940100198 alkylating agent Drugs 0.000 claims 8
239000002168 alkylating agent Substances 0.000 claims 8
150000004820 halides Chemical class 0.000 claims 6
239000012442 inert solvent Substances 0.000 claims 6
125000003545 alkoxy group Chemical group 0.000 claims 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
229910052801 chlorine Inorganic materials 0.000 claims 3
125000001309 chloro group Chemical group Cl* 0.000 claims 3
125000005843 halogen group Chemical group 0.000 claims 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
150000001347 alkyl bromides Chemical class 0.000 claims 2
150000001350 alkyl halides Chemical class 0.000 claims 2
150000001351 alkyl iodides Chemical class 0.000 claims 2
125000004429 atom Chemical group 0.000 claims 2
229910052794 bromium Inorganic materials 0.000 claims 2
229910052799 carbon Inorganic materials 0.000 claims 2
229910052740 iodine Inorganic materials 0.000 claims 2
239000000376 reactant Substances 0.000 claims 2
239000012429 reaction media Substances 0.000 claims 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
150000001348 alkyl chlorides Chemical class 0.000 claims 1
DCVXWERGVUVVLH-UHFFFAOYSA-N azane;isoquinoline Chemical group N.C1=NC=CC2=CC=CC=C21 DCVXWERGVUVVLH-UHFFFAOYSA-N 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical group 0.000 claims 1
125000004433 nitrogen atom Chemical group N* 0.000 claims 1
ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
239000000203 mixture Substances 0.000 description 34
239000000243 solution Substances 0.000 description 33
239000003795 chemical substances by application Substances 0.000 description 27
239000002244 precipitate Substances 0.000 description 20
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
230000002999 depolarising effect Effects 0.000 description 18
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
239000000463 material Substances 0.000 description 15
230000009471 action Effects 0.000 description 14
238000009835 boiling Methods 0.000 description 14
230000000694 effects Effects 0.000 description 14
238000002844 melting Methods 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
230000008018 melting Effects 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 11
239000000047 product Substances 0.000 description 11
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 10
125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
229910021607 Silver chloride Inorganic materials 0.000 description 8
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 8
241000282693 Cercopithecidae Species 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000010438 heat treatment Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
KGPAYJZAMGEDIQ-UHFFFAOYSA-N laudanosine Natural products C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1C KGPAYJZAMGEDIQ-UHFFFAOYSA-N 0.000 description 6
239000000843 powder Substances 0.000 description 6
235000011121 sodium hydroxide Nutrition 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
KGPAYJZAMGEDIQ-KRWDZBQOSA-N Laudanosine Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1C KGPAYJZAMGEDIQ-KRWDZBQOSA-N 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
239000012065 filter cake Substances 0.000 description 5
150000002431 hydrogen Chemical class 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
230000001376 precipitating effect Effects 0.000 description 5
229910052709 silver Inorganic materials 0.000 description 5
239000004332 silver Substances 0.000 description 5
229910001961 silver nitrate Inorganic materials 0.000 description 5
MLKQJVFHEUORBO-UHFFFAOYSA-M silver;methanesulfonate Chemical compound [Ag+].CS([O-])(=O)=O MLKQJVFHEUORBO-UHFFFAOYSA-M 0.000 description 5
ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 4
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
230000037005 anaesthesia Effects 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
150000001649 bromium compounds Chemical group 0.000 description 4
239000000356 contaminant Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
239000000575 pesticide Substances 0.000 description 4
239000012265 solid product Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 4
JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 4
125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 3
ALQIPWOCCJXSKZ-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C)C1CC1=CC(OC)=C(OC)C(OC)=C1 ALQIPWOCCJXSKZ-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
206010021118 Hypotonia Diseases 0.000 description 3
MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 3
241000282560 Macaca mulatta Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
GDMZKPQEBVBXIQ-UHFFFAOYSA-N [Ag].CC(=O)OC1=CC=C(OC(C)=O)C=C1 Chemical compound [Ag].CC(=O)OC1=CC=C(OC(C)=O)C=C1 GDMZKPQEBVBXIQ-UHFFFAOYSA-N 0.000 description 3
239000003708 ampul Substances 0.000 description 3
239000000544 cholinesterase inhibitor Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
125000001033 ether group Chemical group 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 3
229960003054 gallamine Drugs 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
230000036640 muscle relaxation Effects 0.000 description 3
230000002232 neuromuscular Effects 0.000 description 3
GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 3
229960005457 pancuronium Drugs 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
230000035484 reaction time Effects 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
JUDUFOKGIZUSFP-UHFFFAOYSA-M silver;4-methylbenzenesulfonate Chemical compound [Ag+].CC1=CC=C(S([O-])(=O)=O)C=C1 JUDUFOKGIZUSFP-UHFFFAOYSA-M 0.000 description 3
239000007787 solid Substances 0.000 description 3
229940032712 succinylcholine Drugs 0.000 description 3
UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 3
229960001844 tubocurarine Drugs 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 3
229940007718 zinc hydroxide Drugs 0.000 description 3
229910021511 zinc hydroxide Inorganic materials 0.000 description 3
YLCILCNDLBSOIO-UHFFFAOYSA-N (3-prop-2-enoyloxyphenyl) prop-2-enoate Chemical compound C=CC(=O)OC1=CC=CC(OC(=O)C=C)=C1 YLCILCNDLBSOIO-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
206010029315 Neuromuscular blockade Diseases 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
BEQWTZFUPAAWPF-UHFFFAOYSA-N [Ag].C=CC(=O)OC1=CC=C(OC(=O)C=C)C=C1 Chemical compound [Ag].C=CC(=O)OC1=CC=C(OC(=O)C=C)C=C1 BEQWTZFUPAAWPF-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
FGPUFQRNZGCKQV-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-(3,4,5-trimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1=CC(OC)=C(OC)C(OC)=C1 FGPUFQRNZGCKQV-UHFFFAOYSA-N 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229960003424 phenylacetic acid Drugs 0.000 description 2
239000003279 phenylacetic acid Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
230000006794 tachycardia Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
238000002627 tracheal intubation Methods 0.000 description 2
GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
WADJDQQIPSKENN-UHFFFAOYSA-N 1-methoxy-4-methylbenzene Chemical compound [CH2]C1=CC=C(OC)C=C1 WADJDQQIPSKENN-UHFFFAOYSA-N 0.000 description 1
DDSJXCGGOXKGSJ-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)acetic acid Chemical compound COC1=CC(CC(O)=O)=CC(OC)=C1OC DDSJXCGGOXKGSJ-UHFFFAOYSA-N 0.000 description 1
KRXUBZPHAPGHPE-UHFFFAOYSA-N 3-[3-(2-carboxyethenyl)phenyl]prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CC(C=CC(O)=O)=C1 KRXUBZPHAPGHPE-UHFFFAOYSA-N 0.000 description 1
PHJVALKQCXJDNM-UHFFFAOYSA-M 6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydroisoquinolin-2-ium;iodide Chemical compound [I-].C1=2C=C(OC)C(OC)=CC=2CC[N+](C)=C1CC1=CC(OC)=C(OC)C(OC)=C1 PHJVALKQCXJDNM-UHFFFAOYSA-M 0.000 description 1
208000021959 Abnormal metabolism Diseases 0.000 description 1
235000001674 Agaricus brunnescens Nutrition 0.000 description 1
BUQSONMARRFXEA-UHFFFAOYSA-N C1(=CC=C(C=C1)C=CC(=O)O)C=CC(=O)O.C(C=C)(=O)OC1=CC=C(C=C1)OC(C=C)=O.[Ag] Chemical compound C1(=CC=C(C=C1)C=CC(=O)O)C=CC(=O)O.C(C=C)(=O)OC1=CC=C(C=C1)OC(C=C)=O.[Ag] BUQSONMARRFXEA-UHFFFAOYSA-N 0.000 description 1
CWXBDEWSZUSXBC-UHFFFAOYSA-L C1(=CC=C(C=C1)CC(=O)[O-])CC(=O)[O-].[Ag+2] Chemical compound C1(=CC=C(C=C1)CC(=O)[O-])CC(=O)[O-].[Ag+2] CWXBDEWSZUSXBC-UHFFFAOYSA-L 0.000 description 1
102000003914 Cholinesterases Human genes 0.000 description 1
108090000322 Cholinesterases Proteins 0.000 description 1
VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
206010017999 Gastrointestinal pain Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010062530 Increased bronchial secretion Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
OBSFJKTYCAXMFT-UHFFFAOYSA-N [I-].[I-].C1=CC=C2C[NH2+]CCC2=C1.C1=CC=C2C[NH2+]CCC2=C1 Chemical compound [I-].[I-].C1=CC=C2C[NH2+]CCC2=C1.C1=CC=C2C[NH2+]CCC2=C1 OBSFJKTYCAXMFT-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
IZTUINVRJSCOIR-UHFFFAOYSA-N benzylisoquinoline Chemical class N=1C=CC2=CC=CC=C2C=1CC1=CC=CC=C1 IZTUINVRJSCOIR-UHFFFAOYSA-N 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
229940048961 cholinesterase Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229950000405 decamethonium Drugs 0.000 description 1
125000004386 diacrylate group Chemical group 0.000 description 1
125000003963 dichloro group Chemical group Cl* 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
239000003814 drug Substances 0.000 description 1
229960003748 edrophonium Drugs 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
PYGSKMBEVAICCR-UHFFFAOYSA-N hexa-1,5-diene Chemical group C=CCCC=C PYGSKMBEVAICCR-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
230000004220 muscle function Effects 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
230000003387 muscular Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229960002362 neostigmine Drugs 0.000 description 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
UJJUJHTVDYXQON-UHFFFAOYSA-N nitro benzenesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C1=CC=CC=C1 UJJUJHTVDYXQON-UHFFFAOYSA-N 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
150000007925 phenylethylamine derivatives Chemical class 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
102000007739 porin activity proteins Human genes 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000012232 skeletal muscle contraction Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229940120904 succinylcholine chloride Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000002465 tibial artery Anatomy 0.000 description 1
HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/10—Quaternary compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pain & Pain Management (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DD79210690A 1978-07-21 1979-01-29 Verfahren zur herstellung von als neuromuskulaere blockierungsmittel verwendbaren verbindungen DD142547A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US92679478A	1978-07-21	1978-07-21

Publications (1)

Publication Number	Publication Date
DD142547A5 true DD142547A5 (de)	1980-07-02

Family

ID=25453730

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD79210690A DD142547A5 (de)	1978-07-21	1979-01-29	Verfahren zur herstellung von als neuromuskulaere blockierungsmittel verwendbaren verbindungen

Country Status (14)

Country	Link
EP (1)	EP0010119A1 (it)
JP (1)	JPS5517367A (it)
AU (1)	AU522421B2 (it)
CA (1)	CA1125287A (it)
DD (1)	DD142547A5 (it)
DK (1)	DK34979A (it)
ES (1)	ES477257A1 (it)
FI (1)	FI790214A7 (it)
IE (1)	IE790108L (it)
IL (1)	IL56487A (it)
IT (1)	IT1202871B (it)
MC (1)	MC1240A1 (it)
PL (1)	PL121468B1 (it)
ZA (1)	ZA79253B (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8418303D0 (en) *	1984-07-18	1984-08-22	Wellcome Found	Compounds
BG41897A1 (en) *	1985-07-19	1987-09-15	Ivanov	Dichlormethylate of n, n'- 4, 10- dioxa- 3, 11- bis- tetrahydropapaverine and method for its preparation
US5240939A (en) *	1991-10-31	1993-08-31	Anaquest, Inc.	Nitrogen bridge tetrahydroisoquinolines
CN103880744A (zh) *	2012-12-21	2014-06-25	常州工程职业技术学院	一种5’-甲氧基劳丹素的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2662083A (en) *	1950-10-24	1953-12-08	Allen & Hanburys Ltd	Heterocyclic polymethylene-bisquaternary ammonium salts and process for preparing same
GB863717A (en) *	1958-07-03	1961-03-22	Allen & Hanburys Ltd	Tetrahydropapaverine derivatives and their preparation
GB1125619A (en) *	1965-11-15	1968-08-28	Wellcome Found	Derivatives of bis-isoquinolines
AU506657B2 (en) *	1975-12-10	1980-01-17	Wellcome Foundation Limited, The	Isoquinoline derivatives
JPS5455577A (en) *	1977-08-01	1979-05-02	Masachiyuusetsutsu Gen Hosupit	Blocking agent of neuromuscle

1979
- 1979-01-18 CA CA319,886A patent/CA1125287A/en not_active Expired
- 1979-01-22 ZA ZA79253A patent/ZA79253B/xx unknown
- 1979-01-23 IL IL56487A patent/IL56487A/xx unknown
- 1979-01-23 FI FI790214A patent/FI790214A7/fi unknown
- 1979-01-26 AU AU43688/79A patent/AU522421B2/en not_active Ceased
- 1979-01-26 DK DK34979A patent/DK34979A/da not_active Application Discontinuation
- 1979-01-26 MC MC791358A patent/MC1240A1/fr unknown
- 1979-01-29 IT IT19694/79A patent/IT1202871B/it active
- 1979-01-29 DD DD79210690A patent/DD142547A5/de unknown
- 1979-01-29 EP EP79100254A patent/EP0010119A1/en not_active Ceased
- 1979-01-29 ES ES477257A patent/ES477257A1/es not_active Expired
- 1979-01-30 JP JP960879A patent/JPS5517367A/ja active Pending
- 1979-01-30 PL PL1979213098A patent/PL121468B1/pl unknown
- 1979-01-30 IE IE790108A patent/IE790108L/xx unknown

Also Published As

Publication number	Publication date
IL56487A0 (en)	1979-03-12
IL56487A (en)	1983-05-15
PL213098A1 (it)	1980-03-24
ZA79253B (en)	1980-06-25
IT7919694A0 (it)	1979-01-29
JPS5517367A (en)	1980-02-06
AU4368879A (en)	1980-01-24
MC1240A1 (fr)	1979-10-26
AU522421B2 (en)	1982-06-03
EP0010119A1 (en)	1980-04-30
CA1125287A (en)	1982-06-08
IT1202871B (it)	1989-02-15
DK34979A (da)	1980-01-22
IE790108L (en)	1980-01-21
ES477257A1 (es)	1979-08-01
FI790214A7 (fi)	1980-01-22
PL121468B1 (en)	1982-05-31

Publication	Publication Date	Title
DE2655883C2 (it)	1990-02-01
DE2658544C2 (de)	1985-10-03	Carbostyrilderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE1593579B1 (de)	1972-02-03	Hydroxy-cyclohexylamine,deren physiologisch vertraeglichen Saeureadditionssalze und Verfahren zu ihrer Herstellung
US4192877A (en)	1980-03-11	Neuromuscular blocking agents
DE2833505A1 (de)	1979-04-05	Tetrahydro-isochinolin-derivate, verfahren zu deren herstellung und mittel enthaltend die derivate
DE2635961A1 (de)	1977-03-03	Therapeutisch wirksame verbindungen und verfahren zu ihrer herstellung
DE2549889C2 (de)	1985-06-05	3,4-Dihydrocarbostyril-Derivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4235906A (en)	1980-11-25	Bis-isoquinolinium compounds, compositions and methods of use
DD142547A5 (de)	1980-07-02	Verfahren zur herstellung von als neuromuskulaere blockierungsmittel verwendbaren verbindungen
DE2449205C2 (de)	1982-03-11	Substituierte Furylverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2101691A1 (de)	1972-03-16	Isochinolinderivate
DE2327193C3 (de)	1979-11-29	N-(Diethylaminoethyl)-2-methoxy-5methylsulfonylbenzamid, seine Salze, Verfahren zur Herstellung dieser Verbindungen sowie diese Verbindungen enthaltende Arzneimittel
DE2903917C2 (it)	1987-09-24
DE1768671C3 (de)	1974-03-14	N-(tert-Aminoalkyl)-2-alkylen-(oder -alkinyl)-oxybenzamide sowie ihre pharmazeutisch verträglichen Säureadditionssalze und quartären Ammoniumsalze
DE2459630B2 (de)	1980-07-10	2-Pyrimidyl-aminomethylergolinderivate, Verfahren zu ihrer Herstellung und pharmazeutische Mittel
DE2213044C3 (de)	1978-02-09	Racemisches und optisch aktives 1 -(23-Dichlorphenoxy)-3-tert. - butylamino-2-propanol und ihre Salze, Verfahren zu deren Herstellung und Arzneimittel auf Basis dieser Verbindungen
DE1232159B (de)	1967-01-12	Verfahren zur Herstellung von trifluormethylgruppenhaltigen beta-Aminosaeureaniliden
DE2130303C (de)	1973-05-17	N Phosphorylbiguamde und diese enthaltende Arzneimittel
DE2140550C3 (de)	1977-12-29	2-Benzoylalkylbenzomorphane, Verfahren zu ihrer Herstellung und Arzneimittel
AT213395B (de)	1961-02-10	Verfahren zur Herstellung des neuen β-Hydroxybuttersäure-cyclohexylamids
SU1077569A3 (ru)	1984-02-29	Способ получени производных изохинолини
AT315870B (de)	1974-06-10	Verfahren zur Herstellung von neuen Adenin-Derivaten und von deren Salzen
AT339888B (de)	1977-11-10	Verfahren zur herstellung von neuen basischen estern
DE1595875C (de)	1972-08-31	Phenothiazine und Verfahren zu deren Herstellung
DE2130304C (de)	1973-06-07	Phosphorylguamdine